Injection of Autologous Bone Marrow Cells into Damaged Myocardium of No-option Patients with Ischemic Heart Failure, a randomized placebo-controlled trial.

1. Ischemic heart failure NYHA class 2, 3 or 4 despite optimal pharmacological and non- pharmacological therapy;

2. No candidate for (repeat) surgery (revascularization, valve repair or ventricular reconstruction);

3. No candidate for (repeat) percutaneous revascularization;

4. Optimal resynchronization therapy or no candidate for resynchronization therapy;

5. Male or female, > 18 years and < 75 years old;

6. Life expectancy more than 6 months;

7. Able to perform an exercise tolerance test prior to therapy;

8. Able and willing to undergo all the tests used in this protocol including the traveling involved;

9. Written informed consent.

1. Evidence of cancer (except low grade and fully resolved non-melanoma skin malignancy);

2. Concurrent participation in a study using an experimental drug or an experimental procedure within 2 months before randomization;

3. Other severe concurrent illnesses (including active infection, aortic stenosis defined as aortic valve area below 1.0cm2, severe renal insufficiency defined as a GFR <30 mL/min/1.73m2);

4. Bleeding diathesis, HIV infection or pregnancy;

5. Any other condition that, in the opinion of the investigator, could pose a significant threat to the subject if the investigational therapy will be initiated;

6. Inability to undergo cardiac catheterization or nuclear testing;

7. Inability to follow the protocol and comply with follow-up requirements;

8. Candidate for surgery (revascularization, valve repair or ventricular reconstruction), resynchronization therapy or percutaneous revascularization.